PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: A systematic review and meta-analysis

Antonio Rossi, Vincenzo Di Noia, Anastasios Gkountakos, Ettore D'Argento, Giulia Sartori, Emanuele Vita, Sara Monteverdi, Fiorella Lombardo, Roberto Iacovelli, Luisa Carbognin, Isabella Sperduti, Michele Milella, Giampaolo Tortora, Emilio Bria, Sara Pilotto

Research output: Contribution to journalReview article


Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; p = 0.001) and PFS (HR 0.61; p < 0.0001) compared with standard-of-care in NSCLC patients in first-line setting. Conclusion: Immunotherapy-based regimens constantly improved OS and PFS compared with chemotherapy in first-line treatment of nononcogene-addicted NSCLC.

Original languageEnglish
Pages (from-to)921-930
Number of pages10
Issue number10
Publication statusPublished - Jan 1 2019



  • atezolizumab
  • first line
  • immunotherapy
  • meta-analysis
  • nivolumab
  • PD-1
  • PD-L1
  • pembrolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this